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High mobility group box (HMGB) proteins are architectural proteins whose HMG DNA binding domains
confer significant preference for distorted DNA, such as
4-way junctions. HMO1 is one of 10 Saccharomyces cerevisiae HMGB proteins, and it is required for normal
growth and plasmid maintenance and for regulating the
susceptibility of yeast chromatin to nuclease. Using
electrophoretic mobility shift assays, we have shown
here that HMO1 binds 26-bp duplex DNA with Kd ⴝ
39.6 ⴞ 5.0 nM and that its divergent box A domain participates in DNA interactions, albeit with low affinity.
HMO1 has only modest preference for DNA with altered
conformations, including DNA with nicks, gaps, overhangs, or loops, as well as for 4-way junction structures
and supercoiled DNA. HMO1 binds 4-way junctions with
half-maximal saturation of 19.6 ⴞ 2.2 nM, with only a
modest increase in affinity in the absence of magnesium
ions (half-maximal saturation 6.1 ⴞ 1.1 nM). Whereas the
box A domain contributes modest structure-specific
binding, the box B domain is required for high affinity
binding. HMO1 bends DNA, as measured by DNA cyclization assays, facilitating cyclization of 136-, 105-, and
87-bp DNA, but not 75-bp DNA, and it has a significantly
longer residence time on DNA minicircles compared
with linear duplex DNA. The unique DNA binding properties of HMO1 are consistent with global roles in the
maintenance of chromatin structure.

High mobility group (HMG)1 proteins constitute a significant
proportion of non-histone proteins of eukaryotic chromatin.
They are abundant proteins that are grouped, in part based on
their DNA binding characteristics, into three major classes,
HMGA, HMGB, and HMGN (1– 4). HMGB proteins contain one
or more homologous repeats of the ⬃80-amino acid sequence
HMG box and are classified into two families based on the
abundance, function, and DNA specificity of this conserved
region (1, 5, 6). The moderately sequence-specific family is
typified by transcription factors such as sex-determining factor
SRY and lymphoid enhancer factor LEF-1 (7, 8), whereas the
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non-sequence-specific family is represented by so-called architectural factors HMGB1/2 and the Saccharomyces cerevisiae
non-histone chromosomal proteins 6A and 6B (NHP6A/B) (9).
The tertiary structures of HMG boxes from sequence-specific
and non-sequence-specific proteins have revealed an evolutionarily conserved, common global fold consisting of an L-shaped
structure composed of three ␣-helices (10 –19). The HMG DNA
binding domain, which interacts with ⬃10 bp of duplex, binds
to the minor groove of DNA by partial intercalation of one or
two surface-exposed, conserved hydrophobic residues into the
base pair stack. Consequently, the DNA is greatly distorted,
resulting in a sharp bend and helical underwinding (4, 8, 14,
16, 20). SRY and LEF-1 cause bending by insertion of helix I
hydrophobic residues Ile and Met, respectively, into the base
pair stack (Fig. 1) (8, 17). HMGB1 contains tandem HMG box
domains referred to as box A and box B; DNA-intercalating
residues are located at positions 16 and 37 of helices I and II,
respectively, and both can contribute to binding affinity (11, 13,
16, 19). HMGB proteins recognize DNA with structural specificity, binding preferentially to distorted DNA such as 4-way
junctions, minicircles, and cisplatinated DNA, and they supercoil relaxed, topologically closed DNA in the presence of topoisomerase I (11, 16, 20 –25). HMGB proteins have been implicated in diverse biological processes such as transcription,
recombination, replication, and DNA repair by virtue of their
ability to facilitate assembly of nucleoprotein complexes (1,
3, 5).
S. cerevisiae contains 10 HMG box proteins, including the
HMGB1/2 homologs NHP6A/B, ⬃10-kDa proteins with a single
HMG box, that have been shown to participate in the RNA
polymerase II and III transcription systems (9, 26 –28). HMO1
and HMO2 are ⬃25-kDa HMG box proteins, also identified by
homology-based motif prediction programs as having only a single HMG box, in a position corresponding to box B of mammalian
HMGB. However, HMO1 also contains an N-terminal box A
domain with weak similarity to consensus HMG box domains
(Fig. 1). The relative abundance of NHP6A/B and HMO1/2 was
recently determined as part of a global analysis of protein expression in yeast. All four proteins are moderately abundant, with an
estimated 1.9 ⫻ 104 molecules of HMO1/cell compared with ⬃4 ⫻
103 for NHP6A/B and 1.8 ⫻ 103 for HMO2 (29). Strains bearing
HMO1 or HMO2 mutant alleles are viable, although HMO1
mutant strains have growth defects, compromised plasmid maintenance, and nuclease-sensitive chromatin, suggesting that
HMO1 may play a role in stability of the chromatin structure
(30). HMO1 has been shown to interact genetically and physically with FKBP12 prolyl isomerase, a ubiquitous, highly conserved, abundant enzyme that catalyzes a rate-limiting step in
protein folding. Dolinski and Heitman (31) found that mutations
in HMO1 and in the FPR1 gene that encodes FKBP12 are synthetically lethal. A recent study implicates HMO1 as part of the
rRNA transcription apparatus, where it was proposed to function
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FIG. 1. Alignment of HMG box helices I and II. For non-sequence-specific
proteins, box A and box B of rat HMGB1 are
shown along with S. cerevisiae NHP6A, Drosophila melanogaster HMGD, and S. cerevisiae HMO1. The HMO1 box B insertion is
indicated in lowercase. Sequence-specific
proteins are human SRY, mouse LEF-1, and
Xenopus laevis upstream binding factor box
A. Residues corresponding to positions 16
and 37 of HMGB1 helices I and II, respectively, are in bold.

in a similar capacity as the upstream binding factor, which is an
auxiliary factor in the mammalian and amphibian RNA Polymerase I transcription systems. The upstream binding factor has
six HMG domains (32). HMO1 has also recently been shown to
participate in mutagenesis control, but its exact role remains to
be elucidated (33).
We have shown here that the divergent box A domain does
participate in direct DNA contacts and that it contributes modest structure-specific DNA binding to HMO1, whereas box B
confers most of the DNA binding affinity. HMO1 displays a
longer residence time on constrained DNA minicircles, consistent with its role in the maintenance of chromatin structure.
EXPERIMENTAL PROCEDURES

Cloning and Purification of Proteins—The gene encoding HMO1 was
amplified from yeast genomic DNA using primers modified to introduce
NdeI sites at both ends of the PCR product, forward primer, 5⬘-GCCTGTCACCATATGACTACAG-3⬘, and reverse primer, 5⬘-AGTAACGCATATGTCCGTCC-3⬘ (NdeI sites underlined). The HMO1 gene was
cloned into the NdeI site of plasmid pET5a, and plasmid carrying the
HMO1 gene was transformed into Escherichia coli BL21(DE3)pLysS.
HMO1 expression was induced by addition of 1 mM isopropyl-␤-Dthiogalactopyranoside at an A600 of 0.4 and the culture incubated for
3 h. Cells were pelleted and resuspended in lysis buffer (50 mM TrisHCl, pH 8.0, 1 M NaCl, 5% glycerol, 5 mM EDTA, 1 mM 2-mercaptoethanol, 1 mM phenylmethylsulfonyl fluoride (PMSF)). Cells were disrupted by sonication and nucleic acids digested by addition of DNase I
followed by a 1-h incubation on ice. The extract was clarified by centrifugation at 5000 ⫻ g for 20 min. The supernatant was dialyzed
overnight against HA buffer, pH 8.7 (20 mM Tris-HCL, 50 mM KCl, 10%
glycerol, 1 mM EDTA, 4 mM 2-mercaptoethanol, and 1 mM PMSF). The
dialysate was passed through tandem columns of DEAE-cellulose and
CM-Sepharose equilibrated with the same buffer. Proteins were eluted
with a 120-ml linear gradient from 50 mM KCl (HA buffer) to 1 M KCl
(HB buffer: 20 mM Tris-HCl, 1 M KCl, 10% glycerol, 1 mM EDTA, 4 mM
2-mercaptoethanol, 1 mM PMSF). Peak fractions were collected, dialyzed overnight in HA buffer, pH 8.7, and passed through a Heparin
column equilibrated with the same buffer; proteins were eluted and
analyzed as described above. Peak fractions were collected and dialyzed
overnight in HA buffer, pH 7.0. The dialysate was passed through
CM-Sepharose equilibrated with the same buffer, and proteins were
eluted and analyzed as described above. Pure HMO1 fractions were
concentrated and quantitated on Coomassie Blue-stained SDS-PAGE
gels using bovine serum albumin as a standard.
The gene encoding HMO1 was also subcloned into pET28b for expression with an N-terminal His6 tag. Using a PCR-based site-directed
mutagenesis approach, a stop codon was inserted into the HMO1 gene
in place of Pro-91 to create the truncated protein HMO1-BoxA, lacking
box B and the basic tail region, using primers forward, 5⬘-CGCTGCTTGAGTCAAGGCT-3⬘, and reverse, 5⬘-ATAATAGCATCTTTATCATCATCAATAGGG-3⬘. Plasmids HMO1-pET28b and BoxA-pET28b were
transformed into E. coli Rosetta Blue. Cultures were grown to an A600
of 0.2, and expression was induced with 1 mM isopropyl-␤-D-thiogalactopyranoside for 3 h. Cells were pelleted, resuspended in a dialysis/lysis
buffer, pH 7 (50 mM NaxHyPO4, 300 mM NaCl, 10 mM imidazole, 10%
glycerol, 1 mM 2-mercaptoethanol, and 1 mM PMSF), and disrupted by
sonication. Nucleic acids were digested by addition of DNase I followed
by a 1-h incubation on ice. The lysate was dialyzed overnight in dialysis/

lysis buffer. The dialysate was passed through a nickel-nitrilotriacetic
acid column equilibrated with dialysis/lysis buffer and washed with 5
column volumes of wash buffer, pH 7 (50 mM NaxHyPO4, 300 mM NaCl,
20 mM imidazole, 10% glycerol, 1 mM 2-mercaptoethanol, and 1 mM
PMSF). Proteins were eluted with a 50-ml linear gradient from 20 mM
imidazole (wash buffer) to 250 mM imidazole (elution buffer, 50 mM
NaxHyPO4, 300 mM NaCl, 250 mM imidazole, 10% glycerol, 1 mM 2-mercaptoethanol, and 1 mM PMSF) followed by 100 ml of elution buffer.
Pure HMO1 and HMO1-BoxA fractions were quantitated on Coomassie
Blue-stained SDS-PAGE gels using bovine serum albumin as a standard. Bacillus subtilis HU was cloned from B. subtilis genomic DNA and
overexpressed in E. coli. Detailed procedures for its cloning and purification will be reported elsewhere.
Circular Dichroism Spectroscopy—CD spectra were recorded on an
AVIV Model 202 CD spectrophotometer using a 1-cm path length sample cell. Wavelength scans from 200 to 240 nm were performed in
triplicate, and data points were averaged and smoothed using standard
methods. The wavelength scan for His6-tagged HMO1 was recorded at
25 °C with a protein concentration of 0.025 mg/ml in 2.5 mM NaxHyPO4,
pH 7.0, 0.5% glycerol, 10 mM NaCl. The wavelength scan for His6tagged HMO1-BoxA was recorded at 4 °C using a protein concentration
of 0.05 mg/ml in 1 mM Tris, pH 7.0, 0.03% Tween 20, 10% glycerol, 2.8
mM KCl.
Ligase-mediated Circularization—Ligation substrates were prepared by digestion of PCR-amplified or plasmid DNA with appropriate
endonucleases. pET5a was digested with BamHI and BgIII to generate
a 136-bp fragment, whereas BspHI digestion generated a 105-bp fragment. An 87-bp fragment was generated by digestion of pcDNA3 with
SacI. A 75-bp DNA fragment was generated by PCR amplification of the
390 –538-bp region of pUC18 using Taq polymerase and primers 5⬘GCCAGTGCCAAGCTTGCATG-3⬘ and 5⬘-CTTTATGCTCTCGAGTCGTATGTT-3⬘, followed by digestion with SacI. DNA fragments were
purified on 7% (w/v) polyacrylamide gels and 5⬘-end labeled with T4
polynucleotide kinase and [␥-32P]ATP. Reactions were initiated by addition of 20 units of T4 DNA ligase to a final volume of 100 l of reaction
buffer (20 mM Tris-HCl, pH 8, 50 mM NaCl, 10 mM MgCl2, 0.1 mM
Na2EDTA, 1 mM dithiothreitol, 0.05% BRIJ58) containing 1200 fmol
DNA, with or without HMO1. Time points were taken over 90 min. For
each time point, 8 l of the reaction mixture was quenched by addition
of 5 l of stop buffer (75 mM EDTA, 15% glycerol, 0.1% bromphenol blue,
0.1% xylene cyanol, 6 g/l proteinase K). Samples were heated at
55 °C for 15 min and resolved on prerun 7% (w/v) native polyacrylamide
gels (39:1 acrylamide:bisacrylamide) at 4 °C with 0.5⫻ TBE (50 mM Tris
borate, 1 mM EDTA). Quantitation was performed on an Amersham
Biosciences Storm Phosphorimager using software supplied by
the manufacturer.
DNA Supercoiling—Reactions contained 0.2 g of relaxed closed
circular pUC18 plasmid, prepared by adding 2.5 units of Vaccinia
topoisomerase I (Epicentre) to supercoiled pUC18 in 50 mM Tris, pH 7.5,
2.5 mM MgCl2, 100 mM NaCl, and 0.1 mM EDTA. After 1.5 h at 37 °C,
varying amounts of HMO1 were added and the reactions incubated for
1 h at 37 °C. Reactions were quenched with 5 l of termination buffer
(5⫻ TBE, 5% SDS, 15% sucrose, 0.1% bromphenol blue, 0.1% xylene
cyanol, 2 g/l proteinase K) and incubated for 1 h at 37 °C. Samples
were loaded on 1% 1⫻ TBE-agarose gels and electrophoresed at 2 V/cm
for 12 h in 1⫻ TBE buffer.
Agarose Gel Retardation—Reactions were incubated at room temperature in 10 l of reaction buffer containing 0.2 g of linear, relaxed
closed circular or supercoiled pUC18 and varying amounts of HMO1 or
HMO1-BoxA. Complexes were resolved on 0.7% 1⫻ TAE-agarose gels
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and electrophoresed at 2.5 V/cm for 3 h in 1⫻ TAE buffer (40 mM Tris
acetate, 1 mM EDTA, pH 8.0). Gels were stained with ethidium bromide
after electrophoresis.
Electrophoretic Mobility Shift Assays (EMSA) with DNA Minicircles—The 105-bp fragment generated by BspHI digestion of
pET5a DNA was 5⬘-end labeled with T4 polynucleotide kinase and
[␥-32P]ATP. DNA minicircles were generated by intramolecular ligation of the 32P-labeled 105-bp DNA fragment with 20 units of T4 DNA
ligase in the presence of Thermotoga maritima HU for 2 h at room
temperature (34). Samples were treated with Exonuclease III for 1 h
at room temperature and the reactions quenched with stop buffer.
The deproteinised DNA was purified on a 6% (w/v) native polyacrylamide gel (39:1 acrylamide:bisacrylamide).
EMSA was performed with linear and circular 105-bp DNA. Reactions were incubated at room temperature in 10 l of reaction buffer
containing 5 fmol DNA and varying amounts of HMO1. Where indicated, reactions were performed in the absence of MgCl2. Samples were
resolved on prerun 7% (w/v) native polyacrylamide gels (39:1 acrylamide:bisacrylamide) at 4 °C with 0.5⫻ TBE running buffer. Complexes
were visualized by phosphorimaging. In DNA competition assays, 10
fmol of 32P-labeled linear or circular 105-bp DNA was incubated with
HMO1 for 30 min at room temperature to allow complex formation,
followed by addition of varying amounts of linear pUC18 plasmid DNA.
Samples were resolved as described above. For calculating fractional
complex formation, the region on the gel from the slowest migrating
complex to the free DNA was considered as complex.
EMSA with 4-Way DNA Junctions—4-Way junctions were constructed using a published protocol (35); the sequence of individual
strands was as described (36). The 4-way junction was prepared by
annealing the four strands, followed by purification of the junctions on
native polyacrylamide gels. To ensure that all oligonucleotides were
present, aliquots of the purified junctions were run on denaturing gels.
EMSA were performed as described above with 5 fmol DNA and varying
amounts of HMO1 or HMO1-BoxA; for experiments with HMO1-BoxA,
the reaction buffer was modified to contain only 25 mM NaCl, MgCl2
was omitted, and 0.5% Tween 20 was included. In competition assays,
20- or 1000-fold mass excess of unlabeled linear pUC18 DNA was added
after the addition of HMO1. Complexes were resolved and quantified as
described above.
EMSA with Linear Duplex DNA and DNA Containing Loops, Nicks,
Gaps, or Overhangs—Oligonucleotides were purchased and purified by
denaturing gel electrophoresis. Oligonucleotides used to generate constructs with loops, nicks, gaps, or overhangs included a common 37-nt
top strand, 5⬘-CCTAGGCTACACCTACTCTTTGTAAGAATTAAGCTTC-3⬘. To generate 37-bp duplex DNA, complementary oligonucleotides
were mixed at equimolar concentrations, heated at 90 °C, and slowly
cooled to room temperature. To generate looped DNA, a complementary
strand with a pair of 2-nt mismatches with 11-nt spacing (3⬘-GGATCCGATGCCATGAGAAACATAGTTAATTCGAAG-5⬘, with mismatched
nucleotides underlined) was annealed to the top strand. A spacing of 11
bp was chosen as it represents the spacing that yielded optimal complex
formation with mammalian HMGB1 (37). The 37-bp DNA with a central nick, gap, or a 3⬘-overhang was prepared as described (36). The
18-bp duplex corresponded to the sequence of the 5⬘ half of the 37-bp
duplex. The sequence of the 26-bp duplex was 5⬘-CGTGACTACTGTAAGTCGATGATCCG-3⬘. EMSA were performed as described above with
5 fmol DNA. The observed fraction of complex formation was corrected
for dissociation during electrophoresis, and binding isotherms for
HMO1 binding to 26-bp DNA were fitted as described (36). All
experiments were done at least in triplicate, and values are reported as
the mean ⫾ S.D.
Competition assays involving HMO1-BoxA were performed with 32Plabeled 26-bp DNA. Reactions were incubated at room temperature in
10 l of reaction buffer containing 10 fmol DNA, 400 fmol B. subtilis
HU, or 4 pmol full-length HMO1, and varying amounts of HMO1-BoxA.
B. subtilis HU or HMO1 was incubated with DNA at room temperature
for 5 min, followed by addition of HMO1-BoxA. Samples were resolved
on prerun 7% native gels at 4 °C with 0.5⫻ TBE running buffer. Complexes were visualized by phosphorimaging.
RESULTS

DNA Binding by HMO1 and HMO1-BoxA—Recombinant
HMO1 and His6-HMO1 were purified to apparent homogeneity
as judged by Coomassie Blue staining of SDS-PAGE gels. For
analysis of DNA binding by the divergent box A domain, Nterminal His6-tagged HMO1-BoxA was also prepared (Fig. 2A).
CD spectra of both full-length HMO1 and HMO1-BoxA are char-

FIG. 2. HMO1 and HMO1-BoxA have significant ␣-helical content. A, SDS-PAGE gels showing purified His6-HMO1 (left) and His6HMO1-BoxA (right). B and C, CD spectra of HMO1 and
HMO1-BoxA, respectively.

acterized by negative ellipticities at 208 and 222 nm, indicative of
significant ␣-helical content (Fig. 2, B and C). The qualitatively
comparable spectra suggest that HMO1-BoxA is an independently folded domain. The previously reported ability of HMO1 to
self-associate (31), evident at higher protein concentrations, was
also characteristic of the box A domain for which well resolved
CD spectra required the presence of detergent.
DNA binding was analyzed with EMSA. Although no stable
complex could be seen on incubation of 18-bp DNA with fulllength HMO1 (data not shown), a single complex formed with
26-bp DNA (Fig. 3). No difference was seen between N-terminal
His6-tagged and untagged HMO1 (data not shown; all subsequent experiments were performed with untagged HMO1). The
apparent dissociation constant Kd for HMO1 binding to 26-bp
DNA is 39.5 ⫾ 5.0 nM. HMO1 forms two complexes with 37-bp
DNA (Fig. 4A), as seen previously with the mammalian twoHMG box protein HMGB1 (37), suggesting similar site sizes.
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FIG. 3. Electrophoretic analysis of 26-bp DNA titrated with
HMO1. A, reactions contain 5 fmol DNA. Reactions in lanes 2–14
contain 6, 12, 24, 48, 72, 96, 120, 144, 188, 192, 216, 240, and 264 nM
HMO1. B, binding isotherm for HMO1 binding to 26-bp DNA. When
error bars are not shown, they are smaller than the symbol size. Inset
shows purified untagged HMO1 (lane 2). Molecular mass markers are
identified at the left (in kDa).

Half-maximal saturation is observed at 33.1 ⫾ 3.9 nM HMO1.
For reactions performed in the absence of Mg2⫹, the affinity
is slightly higher with half-maximal saturation of 15.6 ⫾ 2.3
nM (data not shown). The lower affinity measured in the
presence of magnesium ions may not be due to effects caused
specifically by the divalent ions but a general effect of raised
ionic strength.
Although no complex is detected upon incubation of 26-bp
DNA with HMO1-BoxA, a competition experiment in which fulllength HMO1 is incubated with 26-bp DNA in the presence of
increasing concentrations of HMO1-BoxA shows a reduction in
HMO1䡠DNA complex formation, suggesting that HMO1-BoxA
competes for binding to the DNA (data not shown). However,
because HMO1-BoxA self-associates, this experiment does not
exclude the possibility that HMO1䡠DNA complex formation is
impaired because of interactions between HMO1-BoxA and fulllength protein. The competition experiment was therefore also
performed using the unrelated architectural protein HU from
B. subtilis (Fig. 5A). Consistent with DNA binding by HMO1BoxA, HU䡠DNA complex formation is also reduced in the presence of HMO1-BoxA. Efficient competition requires micromolar
concentration of HMO1-BoxA, suggesting low affinity binding,
consistent with HMO1-BoxA complexes with 26-bp DNA being
too unstable to detect following electrophoresis.
HMO1 and HMO1-BoxA Have Only Limited Preference for
Distorted DNA—HMGB proteins have been shown to recognize
distorted DNA structures selectively (21, 24, 35, 37, 38). Compared with linear duplex DNA, however, HMO1 did not show
binding preference for DNA with loops, nicks, gaps, or overhangs (data not shown); by comparison, the 37-bp looped DNA
construct served as a preferred substrate for mammalian
HMGB1 (37). Evidently, intrinsic DNA flexibility does not confer a significant energetic advantage for HMO1 to bind DNA.
Surprisingly, HMO1 also had only limited preference for 4-way
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junctions (Fig. 4A). Half-maximal saturation is observed at
19.6 ⫾ 2.2 nM HMO1; for reactions performed in the absence of
Mg2⫹, half-maximal saturation is 6.1 ⫾ 1.1 nM. This is in
distinct contrast to other HMGB proteins that were shown to
bind 4-way junction DNA only in the open square conformation
that is preferred in the absence of Mg2⫹ (39). For comparison,
B. subtilis HU showed the expected preference for the 4-way
junctions compared with linear DNA with a sequence that
corresponds to the longest arms of the 4-way junctions, confirming integrity of the 4-way junction construct (Fig. 4B). As
shown in Fig. 5B, HMO1-BoxA also exhibits a modest preference for 4-way junction DNA; consistent with self-association of
HMO1-BoxA, stable complex formation is enhanced by the
presence of detergent. Notably, the formation of detectable
complexes with a migration pattern similar to that seen for
full-length HMO1 confirms the ability of HMO1-BoxA to engage DNA directly.
When HMO1 was added to reaction mixtures containing both
4-way junction and linear duplex DNA, HMO1 bound with only
modest preference to the 4-way junctions (Fig. 6). In competition assays, EMSA was performed with either 32P-labeled
4-way junctions or 32P-labeled linear duplex DNA in the presence of unlabeled competitor linear or supercoiled plasmid
DNA. HMO1 was competed off the linear and 4-way junction
DNA equally efficiently by linear and supercoiled plasmid DNA
(data not shown). These assays indicated that HMO1 does not
have significant preference for supercoiled compared with linear plasmid DNA. To investigate further the interaction of
HMO1 with different DNA topologies, agarose gel retardation
assays were performed with negatively supercoiled, relaxed,
and linear pUC18 plasmid. As shown in Fig. 7, HMO1 has only
modest preference for supercoiled DNA. Regardless of DNA
topology, HMO1 causes the entire population of DNA to shift as
a rather broad band, suggesting that HMO1 binds without
cooperativity. Consistent with its low affinity binding to 26-bp
DNA, HMO1-BoxA does not form complexes with plasmid DNA
that are detectable following electrophoresis (data not shown).
HMO1 Exhibits a Longer Residence Time on DNA Minicircles—DNA minicircles are circularized DNA shorter than
the persistence length of ⬃150 bp. Because the DNA is highly
constrained, a diminished need for DNA distortion may lower
the free energy of interaction. HMO1 bound 105-bp circular
DNA comparably to 105-bp linear DNA (Fig. 8A). However, in
DNA competition assays with linear pUC18 plasmid, HMO1
was more efficiently competed off linear 105-bp DNA. At 400fold excess plasmid DNA, HMO1 still bound 91% of the 105-bp
circular DNA as opposed to only 13% of the linear 105-bp DNA
(Fig. 8B), suggesting a much longer residence time on the
constrained minicircle.
HMO1 Bends DNA—Ligase-mediated circularization assays
were performed measuring the efficiency with which T4 DNA
ligase mediates ring closure of DNA fragments that are shorter
than the persistence length (20, 40). The ability of HMO1 to
enhance ligase-mediated DNA circularization was qualitatively assessed with 136-, 105-, 87-, 75-, and 65-bp duplex DNA.
HMO1 facilitated formation of circles with DNA of 136, 105,
and 87 bp, but not 75 or 65 bp (Fig. 9). As expected, initial rates
of cyclization were highest for the longer 136-bp DNA; however,
the 87-bp DNA produced monomer circles most efficiently.
Dimer circle formation and multimerization of the 87-bp DNA
occurred in reactions with and without HMO1, although to a
lesser extent compared with the other DNA constructs. The
105-bp DNA yielded the least efficient monomer circle formation. However, more than 50% of the DNA formed dimer circles
even in the absence of the protein, lowering the effective concentration of monomeric DNA and causing the initial rate and
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FIG. 4. Binding of HMO1 and B. subtilis HU to 4-way junctions and linear duplex DNA. A, HMO1. B, B. subtilis HU. Reactions contain
5 fmol DNA, and protein concentrations are 0, 1, 2, 4, 8, 16, 24, 28, 32, 36, 40, and 60 nM (identical for all panels).

ysis of HMO1 purified from yeast, reported that HMO1 could
indeed supercoil relaxed plasmid DNA.
DISCUSSION

FIG. 5. HMO1-BoxA binds DNA. A, HMO1-BoxA competes with
B. subtilis HU for binding to 26-bp DNA. Reactions contain 10 fmol
DNA and 50 nM HU (lanes 2– 8). Reactions in lanes 3– 8 contain 0.2, 0.4,
0.9, 8.8, 17.6, and 26.4 M HMO1-BoxA. B, electrophoretic analysis of
HMO1-BoxA binding to 4-way junction DNA (5 fmol). Reactions in lanes
2–7 contain 2.2, 11, 22, 33, 44, and 66 M HMO1-BoxA.

net yield of monomer circles to be lower than that measured
with 87-bp DNA. Secondly, the different cohesive termini of the
DNA probes are recognized differentially by DNA ligase. By
comparison, S. cerevisiae non-histone protein 6A (NHP6A) can
form monomer circles with DNA substrates of 66 bp (20),
whereas HMGB1/2 and HMG-D can form monomer circles with
DNA substrates as short as 59 and 55 bp, respectively, at high
protein concentrations (41, 42). The protein concentrations
used in our experiments are comparable with the concentrations used for other HMGB proteins; our data therefore indicate that HMO1 bends DNA, although not as effectively as
other HMGB proteins.
HMO1 Does Not Supercoil Relaxed DNA—Many HMGB proteins insert negative supercoils in the presence of topoisomerase I in topologically closed DNA (25, 30, 43). To assess the
ability of HMO1 to supercoil DNA, relaxed closed circular
pUC18 DNA was incubated with increasing amounts of HMO1
(Fig. 10). There was no evidence of DNA supercoiling by HMO1,
nor did HMO1-BoxA supercoil DNA (not shown). This contrasts
with a previous report by Lu et al. (30) who, focusing on anal-

Recent studies have shown that the difference between sequence-specific HMGB proteins and the non-sequence-specific
homologs depends on individual DNA-intercalating residues
and the global features of the HMG box, which determines the
mode of DNA recognition. For the tandem HMG boxes of
HMGB1, the DNA-intercalating residues are at positions 16 or
37, located in helices I and II, respectively, and both can contribute to the binding affinity of the HMG boxes. Box A has an
alanine at position 16, which does not intercalate with the DNA
but forms a hydrophobic contact, whereas phenylalanine at
position 37 is used as a bending wedge (Fig. 1). Box B has a
phenylalanine at position 16 and isoleucine at position 37, both
of which are potential intercalating residues. Sequence-specific
HMGB proteins have polar residues at position 37 that participate in sequence-specific hydrogen bond formation (8, 16, 42,
44). For both box A and B of HMGB1, their ability to bend DNA
is reflected in preferred binding to distorted DNA. Box B, with
its 2 DNA-intercalating residues, introduces the greatest bend,
whereas box A fails to bend DNA effectively (41, 45). Box A has
the greatest preference for distorted DNA due to stacking of the
helix II bending wedge on an exposed base pair, whereas the
affinity of box B for distorted DNA is only modestly greater
than its affinity for duplex DNA (45, 46). Accordingly, the
presence of a hydrophobic DNA-intercalating residue in position 16 of helix I appears to be important for bending, whereas
a bending wedge in helix II may be required for selective
recognition of distorted DNA.
We have found HMO1 to bend DNA but to have only modest
preference for distorted DNA structures, including the 4-way
junction. The HMO1 box A domain is highly divergent from the
consensus, containing a 5-amino acid insertion in the middle of
helix III, including a helix-breaking glycine, that is likely to
affect its structure and mode of DNA interaction. However, our
data showed that the box A domain has significant ␣-helical
content, consistent with an HMG-like fold, and that it is involved in direct DNA contacts (Figs. 2 and 5). DNA bending by
HMO1 would be consistent with the presence of hydrophobic
residues in position 16 of both HMG boxes and the potential
use of Ile-37 of box A as an additional bending wedge. The
limited preference of HMO1 for distorted DNA, combined with
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FIG. 6. HMO1 has only modest preference for 4-way junction DNA. Reactions contain linear duplex DNA and
4-way junctions. HMO1 was added at increasing concentrations, ranging from 10
to 120 nM.

FIG. 7. Binding of HMO1 to supercoiled, relaxed, and linear
DNA. Lanes 1, 8, and 15 with no HMO1 and lanes 2–7, 9 –14, and 16 –21
with increasing amounts of HMO1 (1250 –7500 fmol). Samples were
analyzed on 0.7% agarose gels.

FIG. 9. Time course ligation assay with 87-bp DNA. A, 100 fmol
87-bp linear DNA was incubated without (left panel) or with HMO1 (250
nM, right panel) up to 96 min. Time points were taken at 6, 12, 24, 48,
72, and 96 min. Exonuclease III was added to reactions in lanes 7 and
14 at 48-min time points. Circular ligation products (lane 14) were
resistant to digestion by exonuclease III. B, quantitation of ligation
assays for 136-, 105-, and 87-bp DNA. Effective concentrations of monomeric DNA differ for the three substrates, particularly for the 105-bp
DNA for which formation of 210-bp dimer circles predominates. Initial
rates, therefore, do not correlate with duplex length.

FIG. 8. A, binding of HMO1 to linear and circular 105-bp DNA. EMSA
with 10 fmol DNA. Lanes 2– 6 and 8 –12 contain 2.5, 10, 25, 50, 75 nM
HMO1, respectively. B, DNA competition assay. HMO1 (5 pmol) was
incubated with 10 fmol linear (left panel) or circular (right panel) 105-bp
DNA and titrated with unlabeled linear pUC18 DNA. Lanes 3, 4, 5 and
8, 9, 10 contain 4-, 40-, and 400-fold excess of pUC18, respectively.

the low affinity binding of HMO1-BoxA that is also only modestly enhanced by the presence of pre-bent DNA conformations,
suggests that box A contributes the modest structure specificity, whereas box B, which has no hydrophobic residue at position 37, confers most of the DNA binding affinity. The contribution of box A to DNA interactions is also consistent with the
occluded site size for HMO1, which fails to form a stable complex on 18-bp DNA but forms two complexes on 37-bp DNA
(Fig. 4) as also seen for the mammalian two-HMG box protein
HMGB1 (37).

FIG. 10. HMO1 does not supercoil relaxed DNA. Lanes 1 and 2
contain supercoiled (S) and relaxed (R) pUC18 DNA, respectively. Increasing amounts of HMO1 (1250 –7500 fmol) in lanes 3– 6 and BsuHU
(1250 –7500 fmol) in lanes 7–10 were added to relaxed circular DNA.

Ligase-mediated circularization of small DNA fragments has
been extensively utilized as a means of comparing the DNA
bending activities of non-sequence-specific DNA-bending proteins. Both HMGB1/2 and NHP6A/B catalyze formation of
66-bp circles, although NHP6A/B are more efficient (13, 41, 47).
This high efficiency has been attributed to the relative stability
of NHP6A/B䡠DNA complexes compared with HMGB1/2 and HU
complexes (13, 41) but could also be due to a difference in the
bend angle exerted by these proteins, with the angle exerted by
NHP6A/B facilitating DNA strand recognition by ligase (13).
HMO1 facilitated formation of circles only with DNA longer
than 87 bp (Fig. 9), a lower efficiency that may correspond to
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either a reduced bend angle or a short residence time of HMO1
on linear DNA.
Work by Lu et al. (30) reports that HMO1 introduces negative supercoils into relaxed plasmid DNA and that at high
concentrations HMO1 inhibits the unwinding reaction. We did
not find evidence that HMO1 has the capability to introduce
supercoils into relaxed plasmid DNA (Fig. 10). In our work, we
used recombinant HMO1, whereas Lu et al. purified HMO1
from yeast on the basis of its association with a DNA helicase
activity, potentially resulting in isolation of posttranslationally
modified protein (30). SRY, which is a modestly sequencespecific HMGB protein, also failed to supercoil relaxed DNA in
the presence of topoisomerase I (45). At position 37 of helix II,
where intercalating hydrophobic residues are located for nonsequence-specific HMGB proteins, SRY has asparagine (Fig. 1).
Because the HMO1 box B and SRY both lack a hydrophobic
residue at position 37, this may correlate with their intrinsic
inability to supercoil relaxed DNA.
DNA minicircles most likely resemble possible distorted
DNA targets, including features of chromatin structure, DNA
topology during recombination, or bends introduced during
transcription initiation. For HMO1, a much higher mass excess
of plasmid DNA was required to compete for binding compared
with complexes involving linear DNA (Fig. 8). Presumably, the
complex formed with the minicircle is less dynamic compared
with complexes involving linear DNA. This increased residence
time is probably a consequence of an optimized fit between the
minicircle and HMO1. The more stable association of HMO1
with constrained DNA is consistent with its role in maintaining
the integrity of chromatin and in assembly of the rRNA preinitiation complex (30, 32).
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